Cancer Causes & Control

, Volume 21, Issue 12, pp 2195–2201 | Cite as

Association between body mass index and mortality in patients with glioblastoma mutliforme

  • Lee W. Jones
  • Francis Ali-Osman
  • Eric Lipp
  • Jennifer E. Marcello
  • Bridget McCarthy
  • Lucie McCoy
  • Terri Rice
  • Margaret Wrensch
  • Dora Il’yasova
Original paper



To examine the association between obesity and survival in patients with glioblastoma mutliforme (GBM)


Using a prospective design, 1,259 patients with previously untreated GBM were recruited between 1991 and 2008. Height and weight were self-reported or abstracted from medical records at study entry and used to calculate body mass index (BMI) [weight (kg)/[height (m)]2. Cox proportional models were used to estimate the risk of death associated with BMI as a continuous variable or categorized using established criteria (normal weight, 18.5–24.9 kg/m2; overweight, 25.0–29.9 kg/m2; obese, ≥30.0 kg/m2).


Median follow-up was 40 months, and 1,069 (85%) deaths were observed during this period. For all patients, minimal adjusted analyses indicated no significant association between BMI treated as a continuous variable and survival. Compared with patients with a BMI 18.5–24.9 kg/m2, the minimally adjusted HR for overall survival was 1.08 (95% CI, 0.94–1.24) for a BMI 25–29.9 kg/m2 and 1.08 (95% CI, 0.91–28) for a BMI ≥30.0 kg/m2. After additional adjustment for adjuvant therapy, the HR for those with a BMI of 25.0–29.9 kg/m2 was 1.14 (95% CI, 0.99–1.32) and 1.09 (95% CI, 0.91–1.30) for those with a BMI ≥30.0 kg/m2. No significant interactions were revealed for BMI and any demographic variables.


BMI was not associated with survival in newly diagnosed and previously untreated patients with GBM. Further research investigating the prognostic significance of alternative, quantitative measures of body habitus, and functional performance are required.


Epidemiology Glioblastoma Survival Prognosis Body weight Energy balance 



The study was funded by NIH grants CA108786-04, CA52689, CA097257, Robert J. and Helen H. Glaser Family Foundation and Elvira Olsen Family Fund. LWJ is supported by NIH CA143254, CA142566, CA138634, CA133895, CA125458 and funds from George and Susan Beischer.


  1. 1.
    Reardon DA, Desjardins A, Rich JN, Vredenburgh JJ (2008) The emerging role of anti-angiogenic therapy for malignant glioma. Curr Treat Options Oncol 9:1–22CrossRefPubMedGoogle Scholar
  2. 2.
    Stupp R, Mason WP, Van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996CrossRefPubMedGoogle Scholar
  3. 3.
    Mirimanoff RO, Gorlia T, Mason W, Van den Bent MJ, Kortmann RD, Fisher B, Reni M, Brandes AA, Curschmann J, Villa S, Cairncross G, Allgeier A, Lacombe D, Stupp R (2006) Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 24:2563–2569CrossRefPubMedGoogle Scholar
  4. 4.
    Affronti ML, Heery CR, Herndon JE II, Rich JN, Reardon DA, Desjardins A, Vredenburgh JJ, Friedman AH, Bigner DD, Friedman HS (2009) Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer 115:3501–3511CrossRefPubMedGoogle Scholar
  5. 5.
    Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, Eisenhauer E, Belanger K, Brandes AA, Allgeier A, Lacombe D, Stupp R (2008) Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981–22981/CE.3. Lancet Oncol 9:29–38CrossRefPubMedGoogle Scholar
  6. 6.
    Calle EE (2007) Obesity and cancer. BMJ 335:1107–1108CrossRefPubMedGoogle Scholar
  7. 7.
    Calle EE, Kaaks R (2004) Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4:579–591CrossRefPubMedGoogle Scholar
  8. 8.
    Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625–1638CrossRefPubMedGoogle Scholar
  9. 9.
    Li CI, Daling JR, Porter PL, Tang MT, Malone KE (2009) Relationship between potentially modifiable lifestyle factors and risk of second primary contralateral breast cancer among women diagnosed with estrogen receptor-positive invasive breast cancer. J Clin Oncol 27:5312–5318CrossRefPubMedGoogle Scholar
  10. 10.
    de Azambuja E, McCaskill-Stevens W, Francis P, Quinaux E, Crown JP, Vicente M, Giuliani R, Nordenskjold B, Gutierez J, Andersson M, Vila MM, Jakesz R, Demol J, Dewar J, Santoro A, Lluch A, Olsen S, Gelber RD, Di Leo A, Piccart-Gebhart M (2010) The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial. Breast Cancer Res Treat 119:145–153Google Scholar
  11. 11.
    Chen X, Lu W, Zheng W, Gu K, Chen Z, Zheng Y, Shu XO (2010) Obesity and weight change in relation to breast cancer survival. Breast Cancer Res Treat 823–833Google Scholar
  12. 12.
    Dignam JJ, Polite BN, Yothers G, Raich P, Colangelo L, O’Connell MJ, Wolmark N (2006) Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst 98:1647–1654CrossRefPubMedGoogle Scholar
  13. 13.
    Haydon AM, Macinnis RJ, English DR, Giles GG (2006) Effect of physical activity and body size on survival after diagnosis with colorectal cancer. Gut 55:62–67CrossRefPubMedGoogle Scholar
  14. 14.
    Jayachandran J, Banez LL, Aronson WJ, Terris MK, Presti JC Jr, Amling CL, Kane CJ, Freedland SJ (2009) Obesity as a predictor of adverse outcome across black and white race: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Cancer 115:5263–5271CrossRefPubMedGoogle Scholar
  15. 15.
    Kanashiki M, Sairenchi T, Saito Y, Ishikawa H, Satoh H, Sekizawa K (2005) Body mass index and lung cancer: a case-control study of subjects participating in a mass-screening program. Chest 128:1490–1496CrossRefPubMedGoogle Scholar
  16. 16.
    Franceschi S, Dal Maso L, Levi F, Conti E, Talamini R, La Vecchia C (2001) Leanness as early marker of cancer of the oral cavity and pharynx. Ann Oncol 12:331–336CrossRefPubMedGoogle Scholar
  17. 17.
    Halabi S, Ou SS, Vogelzang NJ, Small EJ (2007) Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer. Cancer 110:1478–1484CrossRefPubMedGoogle Scholar
  18. 18.
    Halabi S, Small EJ, Vogelzang NJ (2005) Elevated body mass index predicts for longer overall survival duration in men with metastatic hormone-refractory prostate cancer. J Clin Oncol 23:2434–2435 author reply 2435, 2005CrossRefPubMedGoogle Scholar
  19. 19.
    Il’yasova D, Marcello JE, McCoy L, Rice T, Wrensch M (2009) Total dietary antioxidant index and survival in patients with glioblastoma multiforme. Cancer Causes Control 20(8):1255–1260 Google Scholar
  20. 20.
    Rock CL, Demark-Wahnefried W (2002) Nutrition and survival after the diagnosis of breast cancer: a review of the evidence. J Clin Oncol 20:3302–3316CrossRefPubMedGoogle Scholar
  21. 21.
    Jones LW, Friedman AH, West MJ, Mabe SK, Fraser J, Kraus WE, Friedman HS, Tresch MI, Major N, Reardon DA (2010) Quantitative assessment of cardiorespiratory fitness, skeletal muscle function, and body composition in adults with primary malignant glioma. Cancer 116:695–704Google Scholar
  22. 22.
    Antoun S, Baracos VE, Birdsell L, Escudier B, Sawyer MB (2010) Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann OncolGoogle Scholar
  23. 23.
    Antoun S, Birdsell L, Sawyer MB, Venner P, Escudier B, Baracos VE (2010) Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results From a placebo-controlled study. J Clin Oncol 1054–1060Google Scholar
  24. 24.
    Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, Baracos VE (2008) Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 9:629–635CrossRefPubMedGoogle Scholar
  25. 25.
    Jones LW, Mourtzakis M, Peters KB, Friedman AH, West MJ, Mabe S, Kraus WE, friedman HS, Reardon DA (2010) Changes in functional performance measures in adults undergoing chemoradiation for primary malignant glioma. Oncologist 15:636–647Google Scholar
  26. 26.
    Derr RL, Ye X, Islas MU, Desideri S, Saudek CD, Grossman SA (2009) Association between hyperglycemia and survival in patients with newly diagnosed glioblastoma. J Clin Oncol 27:1082–1086CrossRefPubMedGoogle Scholar
  27. 27.
    Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8:915–928CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2010

Authors and Affiliations

  • Lee W. Jones
    • 1
  • Francis Ali-Osman
    • 2
    • 3
  • Eric Lipp
    • 2
  • Jennifer E. Marcello
    • 5
  • Bridget McCarthy
    • 4
  • Lucie McCoy
    • 6
  • Terri Rice
    • 6
  • Margaret Wrensch
    • 6
  • Dora Il’yasova
    • 2
    • 7
  1. 1.Department of Radiation OncologyDuke University Medical CenterDurhamUSA
  2. 2.Preston Robert Tisch Brain Tumor CenterDuke University Medical CenterDurhamUSA
  3. 3.Department of SurgeryDuke University Medical CenterDurhamUSA
  4. 4.Division of Epidemiology and BiostatisticsUniversity of Illinois at ChicagoChicagoUSA
  5. 5.Cancer Center BiostatisticsDuke University Medical CenterDurhamUSA
  6. 6.Department of Neurological SurgeryUniversity of California San FranciscoSan FranciscoUSA
  7. 7.Department of Community and Family MedicineDuke University Medical CenterDurhamUSA

Personalised recommendations